MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
Log in

OTCMKTS:IPIXInnovation Pharmaceuticals Stock Price, Forecast & News

$0.32
-0.02 (-5.88 %)
(As of 07/7/2020 12:42 PM ET)
Add
Compare
Today's Range
$0.30
Now: $0.32
$0.36
50-Day Range
$0.14
MA: $0.25
$0.48
52-Week Range
$0.05
Now: $0.32
$0.65
Volume2.29 million shs
Average Volume3.05 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. The company's lead drug compound is Brilacidin, which is in Phase II study for the treatment of oral mucositis, inflammatory bowel disease, and acute bacterial skin and skin structure infection. It also develops Prurisol, a Phase IIb compound, which is in development for psoriasis; and Kevetrin, a lead anti-cancer compound for treating ovarian cancer. In addition, the company owns other candidates for treating diseases, including autism, arthritis, asthma, MS/ALS/Parkinson's, cancer, hypertensive emergency, and bacterial and fungal infections. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Beverly, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IPIX
CUSIPN/A
Phone(978) 236-8717

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees8
Next Earnings DateN/A
OptionableNot Optionable

Receive IPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for IPIX and its competitors with MarketBeat's FREE daily newsletter.

Innovation Pharmaceuticals (OTCMKTS:IPIX) Frequently Asked Questions

How has Innovation Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Innovation Pharmaceuticals' stock was trading at $0.1250 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IPIX stock has increased by 156.0% and is now trading at $0.32. View which stocks have been most impacted by Coronavirus.

Has Innovation Pharmaceuticals been receiving favorable news coverage?

Headlines about IPIX stock have been trending negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Innovation Pharmaceuticals earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Innovation Pharmaceuticals.

Who are some of Innovation Pharmaceuticals' key competitors?

What other stocks do shareholders of Innovation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovation Pharmaceuticals investors own include Broadcom (AVGO), Inovio Pharmaceuticals (INO), ServiceNow (NOW), Dropbox (DBX), Shopify (SHOP), Vaxart (VXRT), American Express (AXP), Co-Diagnostics (CODX), salesforce.com (CRM) and Cisco Systems (CSCO).

Who are Innovation Pharmaceuticals' key executives?

Innovation Pharmaceuticals' management team includes the following people:
  • Mr. Leo Ehrlich, Chairman, CEO, CFO, Principal Accounting Officer & Sec. (Age 61)
  • Dr. Arthur Peter Bertolino, Pres, Chief Medical Officer & Director (Age 64)
  • Ms. Jane Harness, Sr. VP of Clinical Sciences & Portfolio Management (Age 51)
  • Dr. W. James Alexander M.D., MPH, FACP, Consultant (Age 69)
  • Dr. Paul Ginsburg, Scientific Advisor & Member of Advisory Board

What is Innovation Pharmaceuticals' stock symbol?

Innovation Pharmaceuticals trades on the OTCMKTS under the ticker symbol "IPIX."

How do I buy shares of Innovation Pharmaceuticals?

Shares of IPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innovation Pharmaceuticals' stock price today?

One share of IPIX stock can currently be purchased for approximately $0.32.

What is Innovation Pharmaceuticals' official website?

The official website for Innovation Pharmaceuticals is www.cellceutix.com.

How can I contact Innovation Pharmaceuticals?

Innovation Pharmaceuticals' mailing address is 100 Cummings Ctr Ste 151b, BEVERLY, MA 01915-6117, United States. The company can be reached via phone at (978) 236-8717.

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.